Ascletis Pharma Inc.

Ascletis Received IND Approval and Management Outlook of 2019 and Beyond
2019-08-05
Ascletis to Attend Goldman Sachs China Healthcare Corporate Day 2019
2019-06-24
3-V Biosciences Commences Dosing in Phase 2 Clinical Study of the FASN Inhibitor TVB-2640 in Patients with NASH
2019-05-02
Ganovo is Eligible for the Basic Medical Insurance of Zhejiang Province - Reimbursement-by-disease
2019-04-15
Ascletis Appoints Former MSD Global Vice President Dr. Zhengqing Li as Chief Medical Officer and President of R&D Greater China
2019-03-01
Ascletis and 3-V Biosciences Announce NASH Strategic License and Series E Financing
2019-02-13
Dr. Jinzi J. Wu to Speak at the 19th Annual Conference of China Entrepreneurs Forum
2019-02-12
Dr. Jinzi J. Wu to Speak at the 21st Annual BIO CEO & Investor Conference in New York City
2019-02-07
Ascletis and Alphamab Announce Strategic Collaboration and Licensing Agreement for Anti-PD-L1 to Treat Hepatitis B and Other Viral Diseases
2019-01-14
Ascletis Presented at the LeadingBiotech: East/West CEO
2019-01-07

2

© 2018 Ascletis Pharma Inc. All Rights Reserved
浙公网安备 33010802003344号浙ICP备11050387号-1